Actuate Therapeutics Common Stock Market Value
| ACTU Stock | 4.33 0.09 2.12% |
| Symbol | Actuate |
Is there potential for Biotechnology market expansion? Will Actuate introduce new products? Factors like these will boost the valuation of Actuate Therapeutics. If investors know Actuate will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Actuate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Actuate Therapeutics is measured differently than its book value, which is the value of Actuate that is recorded on the company's balance sheet. Investors also form their own opinion of Actuate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Actuate Therapeutics' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Actuate Therapeutics' market value can be influenced by many factors that don't directly affect Actuate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Actuate Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Actuate Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Actuate Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Actuate Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Actuate Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Actuate Therapeutics.
| 11/17/2025 |
| 02/15/2026 |
If you would invest 0.00 in Actuate Therapeutics on November 17, 2025 and sell it all today you would earn a total of 0.00 from holding Actuate Therapeutics Common or generate 0.0% return on investment in Actuate Therapeutics over 90 days. Actuate Therapeutics is entity of United States More
Actuate Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Actuate Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Actuate Therapeutics Common upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.11) | |||
| Maximum Drawdown | 20.01 | |||
| Value At Risk | (8.67) | |||
| Potential Upside | 6.79 |
Actuate Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Actuate Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Actuate Therapeutics' standard deviation. In reality, there are many statistical measures that can use Actuate Therapeutics historical prices to predict the future Actuate Therapeutics' volatility.| Risk Adjusted Performance | (0.06) | |||
| Jensen Alpha | (0.50) | |||
| Total Risk Alpha | (0.70) | |||
| Treynor Ratio | (0.21) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Actuate Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Actuate Therapeutics February 15, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.06) | |||
| Market Risk Adjusted Performance | (0.20) | |||
| Mean Deviation | 3.23 | |||
| Coefficient Of Variation | (1,115) | |||
| Standard Deviation | 4.23 | |||
| Variance | 17.88 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.50) | |||
| Total Risk Alpha | (0.70) | |||
| Treynor Ratio | (0.21) | |||
| Maximum Drawdown | 20.01 | |||
| Value At Risk | (8.67) | |||
| Potential Upside | 6.79 | |||
| Skewness | 0.1078 | |||
| Kurtosis | 0.3938 |
Actuate Therapeutics Backtested Returns
Actuate Therapeutics secures Sharpe Ratio (or Efficiency) of -0.0982, which signifies that the company had a -0.0982 % return per unit of risk over the last 3 months. Actuate Therapeutics Common exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Actuate Therapeutics' Mean Deviation of 3.23, standard deviation of 4.23, and Risk Adjusted Performance of (0.06) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.81, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Actuate Therapeutics will likely underperform. At this point, Actuate Therapeutics has a negative expected return of -0.42%. Please make sure to confirm Actuate Therapeutics' treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if Actuate Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.12 |
Insignificant reverse predictability
Actuate Therapeutics Common has insignificant reverse predictability. Overlapping area represents the amount of predictability between Actuate Therapeutics time series from 17th of November 2025 to 1st of January 2026 and 1st of January 2026 to 15th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Actuate Therapeutics price movement. The serial correlation of -0.12 indicates that less than 12.0% of current Actuate Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.12 | |
| Spearman Rank Test | 0.05 | |
| Residual Average | 0.0 | |
| Price Variance | 0.54 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Actuate Stock Analysis
When running Actuate Therapeutics' price analysis, check to measure Actuate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Actuate Therapeutics is operating at the current time. Most of Actuate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Actuate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Actuate Therapeutics' price. Additionally, you may evaluate how the addition of Actuate Therapeutics to your portfolios can decrease your overall portfolio volatility.